This study is
approved consistent with the revised supporting statement
(10/18/05). The study design is appropriate for the purpose of the
study identified in the supporting statement. However, in
describing the qualitative information collected, FDA will clearly
acknowledge that the results are not representative of the
industry's attitudes, knowledge, etc.
Inventory as of this Action
Requested
Previously Approved
04/30/2006
04/30/2006
1
0
0
35
0
0
0
0
0
New legislation (MDUFMA 2) is being
contemplated to reauthorize the user fee program before it sunsets
in 2007. FDA would like to understand industry's perspective on
what worked and what did not work in MDUFMA, as well as what
changes industry would like to see if MDUFMA is reauthorized. FDA
is using a third party contractor to conduct an analysis of
industry members on this topic. A third party is being used to
obtain unbiased analyses and conclusions.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.